Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

as these two companies also offer PFA systems in the United States to treat AFib, an abnormal heart rhythm. Medtronic’s PulseSelect PFA device was approved in the United States in December 2023 ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Medtronic (NYSE: MDT) today reported study results highlighting AFib detection with its Linq family of insertable cardiac monitors (ICM).

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common complication being pericardial tamponade (1.1%), and a few cases of stroke (0.7%) ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation system in a larger group of patients with atrial fibrillation.

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to treat atrial fibrillation ... (mAb), for the treatment of early ...